Adiponectin induced AMP-activated protein kinase impairment mediates insulin resistance in Bama mini-pig fed high-fat and high-sucrose diet

다국어 초록 (Multilingual Abstract)

Objective: Adipose tissue is no longer considered as an inert storage organ for lipid, but instead is thought to play an active role in regulating insulin effects via secretion adipokines. However, conflicting reports have emerged regarding the effects of adipokines. In this study, we investigated the role of adipokines in glucose metabolism and insulin sensitivity in obese Bama mini-pigs.
Methods: An obesity model was established in Bama mini-pigs, by feeding with high-fat and high-sucrose diet for 30 weeks. Plasma glucose and blood biochemistry levels were measured, and intravenous glucose tolerance test was performed. Adipokines, including adiponectin, interleukin-6 (IL-6), resistin and tumor necrosis factor alpha (TNF-α), and glucose-induced insulin secretion were also examined by radioimmunoassay. AMP-activated protein kinase (AMPK) phosphorylation in skeletal muscle, which is a useful insulin resistance marker, was examined by immunoblotting. Additionally, associations of AMPK phosphorylation with plasma adipokines and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed by Pearce's correlation analysis.
Results: Obese pigs showed hyperglycemia, high triglycerides, and insulin resistance. Adiponectin levels were significantly decreased (p<0.05) and IL-6 amounts dramatically increased (p<0.05) in obese pigs both in serum and adipose tissue, corroborating data from obese mice and humans. However, circulating resistin and TNF-α showed no difference, while the values of TNF-α in adipose tissue were significantly higher in obese pigs, also in agreement with data from obese humans but not rodent models. Moreover, strong associations of skeletal muscle AMPK phosphorylation with plasma adiponectin and HOMA-IR index were obtained.
Conclusion: AMPK impairment induced by adiponectin decrease mediates insulin resistance in high-fat and high-sucrose diet induction. In addition, Bama mini-pig has the possibility of a conformable model for human metabolic diseases.

참고문헌 (Reference)

1 Steinberg GR, "Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling" 4 : 465-474, 2006

2 Chen H, "The susceptibility of three strains of Chinese minipigs to diet-induced type 2 diabetes mellitus" 38 : 355-363, 2009

3 Ghosh S, "The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications" 305 : 27-34, 2003

4 Sarvas JL, "The IL-6 Paradox: Context Dependent Interplay of SOCS3 and AMPK" (Suppl 13) : 2013

5 Kusminski CM, "Role of resistin in obesity, insulin resistance and Type II diabetes" 109 : 243-256, 2005

6 Barnes KM, "Role of resistin in insulin sensitivity in rodents and humans" 10 : 96-107, 2009

7 Huang X, "Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans" 39 : 607-615, 2016

8 Nogueiras R, "Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner" 548 : 21-27, 2003

9 Mohamed-Ali V, "Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo" 277 : E971-E975, 1999

10 Okada-Iwabu M, "Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity" 39 : 363-372, 2015

11 Kim JY, "Obesity-associated improvements in metabolic profile through expansion of adipose tissue" 117 : 2621-2637, 2007

12 Cois A, "Obesity trends and risk factors in the South African adult population" 2 : 42-, 2015

13 Dufrane D, "Nutrient control of insulin secretion in perifused adult pig islets" 33 : 430-438, 2007

14 Hojlund K, "Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance" 61 : B4890-, 2014

15 Carey AL, "Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase" 55 : 2688-2697, 2006

16 Rorsman P, "Insulin granule dynamics in pancreatic beta cells" 46 : 1029-1045, 2003

17 Perry RJ, "Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes" 160 : 745-758, 2015

18 Ng M, "Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013" 384 : 766-781, 2014

19 Henquin JC, "Dynamics of glucose-induced insulin secretion in normal human islets" 309 : E640-E650, 2015

20 Koopmans SJ, "Considerations on pig models for appetite, metabolic syndrome and obese type 2 diabetes: From food intake to metabolic disease" 759 : 231-239, 2015

21 Lee JH, "Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia" 288 : E625-E632, 2005

22 Fernandez-Real JM, "Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women" 86 : 1154-1159, 2001

23 Wascher TC, "Chronic TNF-alpha neutralization does not improve insulin resistance or endothelial function in 'healthy' men with metabolic syndrome" 17 : 189-193, 2011

24 Papaetis GS, "Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns" 11 : 463-482, 2015

25 Yannakoulia M, "Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans" 88 : 1730-1736, 2003

26 Coelho M, "Biochemistry of adipose tissue: an endocrine organ" 9 : 191-200, 2013

27 Booth A, "Adipose tissue: an endocrine organ playing a role in metabolic regulation" 2016

28 Bluher M, "Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance?" 130 : 1603-1614, 2016

29 Esfahani M, "Adiponectin: an adipokine with protective features against metabolic syndrome" 18 : 430-442, 2015

30 Yamauchi T, "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase" 8 : 1288-1295, 2002

31 Ruan H, "Adiponectin signaling and function in insulin target tissues" 2016

32 Xita N, "Adiponectin in diabetes mellitus" 19 : 5451-5458, 2012

33 Antuna-Puente B, "Adipokines: the missing link between insulin resistance and obesity" 34 : 2-11, 2008

34 Lehr S, "Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders" 6 : 91-101, 2012

35 Barbosa-Cortes L, "Adipokines, insulin resistance, and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country" 17 : 125-, 2017

36 Coles CA, "Adipokines in Healthy Skeletal Muscle and Metabolic Disease" 900 : 133-160, 2016

37 Maury E, "Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome" 314 : 1-16, 2010

38 Ruderman NB, "AMPK, insulin resistance, and the metabolic syndrome" 123 : 2764-2772, 2013

39 Coughlan KA, "AMPK activation: a therapeutic target for type 2 diabetes?" 7 : 241-253, 2014

40 Kim SJ, "A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus" 13 : 811-822, 2014